| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| McCulloch Kevin | President and Chief Operating Officer | C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO | /s/ Beth Hecht, Attorney-in-Fact | 04 Aug 2025 | 0002031695 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XERS | Common Stock | Tax liability | $78,822 | -14,651 | -0.85% | $5.38 | 1,701,159 | 01 Aug 2025 | Direct | F1, F2 |
| holding | XERS | Common Stock | 25,000 | 01 Aug 2025 | By Spouse | F3 | |||||
| holding | XERS | Common Stock | 2,000 | 01 Aug 2025 | By Charles R. McCulloch Trust dated 1990 | F3 |
| Id | Content |
|---|---|
| F1 | Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2025. |
| F2 | These shares include 7,225 shares that were purchased on June 30, 2025 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. |
| F3 | The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
President and Chief Operating Officer